Commercially available in the
US as Gohibic since 06 2023
InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including critical COVID-19.
The program is being funded by grants from the German Ministry of Research and Education along with the German Ministry of Health.
InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Pyoderma Gangraenosum (PG), a rare ulcerative skin disorder.
InflaRx recently released positive interim results from three cohorts in its’ Phase II clinical study to investigate a potential benefit of vilobelimab for patients suffering from PG. In Q4’21, this study completed its treatment period with the observation period to be completed in the 1H’22.
PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)
InflaRx has entered into a clinical collaboration agreement with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) to evaluate the combination of vilobelimab and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with a PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC). In June 2021, the first patient was dosed in a Phase IIa clinical study with two vilobelimab arms, including one with KEYTRUDA®.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, U.S.A, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Single ascending dose and
multiple ascending dose
phase I study ongoing
INF904 is a promising oral, low molecular weight drug development candidate that targets the C5aR receptor with high affinity and selectivity. InflaRx is targeting complement-mediated, chronic auto-immune and inflammatory conditions where an oral small molecule is the preferred route of administration for patients.
Developing for optimized use
for other chronic inflammatory
IFX002 is an advancement of vilobelimab technology, currently in preclinical development. IFX002 is a highly potent anti-complement C5a antibody, binding to the same epitope of the C5a protein than vilobelimab. With a higher humanization grade, altered pharmacokinetic properties and a strong patent position IFX002 is well positioned as life-cycle management project for vilobelimab.